Published February 2021
| Version v1.0.0
Journal Article
Open
COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
Creators
-
Turner, Paul J.1
- Ansotegui, Ignacio J.2
- Campbell, Dianne E.3
- Cardona, Victoria4
-
Ebisawa, Motohiro5
- El-Gamal, Yehia6
- Fineman, Stanley7
- Geller, Mario
- Gonzalez-Estrada, Alexei8
- Greenberger, Paul Allen9
-
Leung, Agnes S. Y.10
- Levin, Michael E.11
- Muraro, Antonella12
- Borges, Mario Sanchez13
- Senna, Gianenrico14
- Tanno, Luciana K.15
- Thong, Bernard Yu-Hor16
- Worm, Margitta17
- WAO Anaphylaxis Committee
-
1.
Imperial College London
- 2. Hospital Quironsalud Bizkaia
-
3.
University of Sydney
-
4.
Vall d'Hebron Hospital Universitari
-
5.
National Sagamihara Hospital
-
6.
Ain Shams University
-
7.
Emory University
-
8.
Mayo Clinic
-
9.
Northwestern University
-
10.
Chinese University of Hong Kong
-
11.
University of Cape Town
-
12.
University of Padua
-
13.
Centro Médico Docente La Trinidad
-
14.
University of Verona
-
15.
Hospital Sírio-Libanês
-
16.
Tan Tock Seng Hospital
-
17.
Charité - University Medicine Berlin
Abstract
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.Other
original_citation: Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, Fineman S, Geller M, Gonzalez-Estrada A, Greenberger PA, Leung ASY, Levin ME, Muraro A, Borges MS, Senna G, Tanno LK, Thong BYH, Worm M, Comm WAOA. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal. 2021;14(2):10.Acknowledgements
We thank Drs Sophie Farooque and Alessia Baseggio Conrado (London) for reviewing a draft of this manuscript.Files
COVID-19 vaccine-associated anaphylaxis.pdf
Files
(1.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:e22b08bbd1567b944402ca635e8a7a5d
|
1.0 MB | Preview Download |
Additional details
Identifiers
- PMID
- 33558825
Related works
- Is related to
- https://www.sciencedirect.com/science/article/pii/S1939455121000119?via%3Dihub (URL)
Dates
- Created
-
2021-02When the item was originally created.